PI: Dou, Huanyu
BIOGRAPHICAL SKETCH
Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME
POSITION TITLE
Huanyu Dou, MD
Assistant professor
eRA COMMONS USER NAME
DOU.HUANYU
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and
DEGREE
include postdoctoral training.)
INSTITUTION AND LOCATION
YEAR(s)
FIELD OF STUDY
(if applicable)
Weifang Medical College, China
Bar-Ilan University, ISRAEL
University of Nebraska Medical Center
MD
Postdoctoral
Fellow
Postdoctoral
Fellow
1982
Medicine
2000-2001
Neurosciences
2002-2005
Neurovirology,
nanomedicine
A. Positions and Honors.
1982-1985
Physician, Rong Jun Hospital
1985-1990
Physician/Instuctor professor, Department of Medicine, Weifang Medical
College,Shandon, China
1993-1995
Assistant Professor, Physician, Department of Anatomy, Weifang Medical
College, China
1995-2000
Associte Professor,Vice-Director, Department of Anatomy, Center Morphology,
Weifang Medical College, China
2000-2001
Postdoctoral Fellow, Laboratory of Zvi Malik, Unit of Microscopy, Faculty of Life
Sciences of Bar-Ilan University, Israel
2002 – 2005
Fellow, CNND, Department of Pathology/Microbiology, University of Nebraska
Medical Center, Omaha, NE, USA
2005 – 2007
Instructor and Director of Neurotherapeutics Program, Department of
Pharmacology and Experimental Neuroscience and Center for Neurovirology and
Neurodegenerative Disorders (CNND)
2008–present
Assistant professor, Department of Pharmacology and Experimental
Neuroscience and Center for Neurovirology and Neurodegenerative Disorders
(CNND), Center for Drug Delivery and Nanomedicine (CDDN
B. Research Support
Active:
1 P20 RR021937-01A2
09/26/2008 - 06/30/2013
DHHS/NIH/NCRR
$1,473,976
Role: PI of project 3 “Cell-based nanoformulations for brain tumors”
Nebraska Center for Nanomedicine
This proposal seeks to develop an interdisciplinary Nanomedicine Center at the University of
Nebraska Medical Center. We have assembled a team of scientists with specific expertise in
nanomedicine, drug delivery, therapeutics and diagnostics. These will now be joined by
biochemists, pharmacologists, immunologists and neuroscientists. All will work, with singular
focus, to develop the means to best use devices of nanoscale size to improve outcomes for
cancer, neurodegenerative and cardiovascular diseases. Such approaches will deliver drugs to
focal areas of central nervous system disease or directly to tumors. Parallel studies seek
1
PI: Dou, Huanyu
nanotechnologies to improve diagnostic measures and disease monitoring. The anticipated
outcome is to maximize clinical benefits and limit untoward side effects.
5 R01 NS36126-13
PI: Gendelman)
04/01/2008 - 03/31/2013
DHHS/NIH/NINDS
$305,335
Role: Co-I
Nanomedicine and NeuroAIDS
This research proposes to investigate the biophysiological properties of monocytes and monocytederived macrophages that influence cell migration both across the blood-brain barrier and within
the brain. The central hypothesis is that changes in ion channel expression in monocytes and
macrophages following exposure to virus and immune products influences the cell's ability to
change its volume and shape, thus influencing cell migration. Such events are pivotal for
macrophages to enter the brain and to secrete the toxins that underlie the neuropathogenesis of
HIV-1 associated dementia.
C. Selected Publications: (from 41)
 Greenbaum L, Katcoff DJ, Dou H, Gozlan Y, Malik Z. A porphobilinogen deaminase (PBGD)
Ran-binding protein interaction is implicated in nuclear trafficking of PBGD in differentiating
glioma cells. Oncogene. 2003 Vol. 22(34): 5221-8.

Dou H, Birusingh K, Faraci J, Gorantla S, Poluektova LY, Maggirwar SB, Dewhurst S, Gelbard
HA, Gendelman HE. Neuroprotective activities of sodium valproate in a murine model of
human immunodeficiency virus-1 encephalitis. J Neurosci. 2003 Vol. 23(27):9 162-70.

Boska MD, Mosley RL, Nawab M, Nelson JA, Zelivyanskaya M, Poluektova L, Uberti M, Dou
H, Lewis TB, Gendelman HE. Advances in neuroimaging for HIV-1 associated neurological
dysfunction: clues to the diagnosis, pathogenesis and therapeutic monitoring. Current HIV
research. 2004 (2): 61-78.

Poluektova L, Gorantla S, Faraci J, Birusingh K, Dou H, Gendelman HE. Neuroregulatory
events follow adaptive immune-mediated elimination of HIV-1-infected macrophages: studies
in a murine model of viral encephalitis. J Immunol. 2004 Vol. 172(12): 7610-7.

Dou H, Kingsley JD, Mosley RL, Gelbard HA, Gendelman HE. Neuroprotective strategies for
HIV-1 associated dementia. Neurotox Res. 2004 Vol. 6(7-8): 503-21.

Nelson JA*, Dou H*, Ellison B, Uberti M, Xiong H, Anderson E, Mellon M, Gelbard HA, Boska
M, Gendelman HE. Coregistration of quantitative proton magnetic resonance spectroscopic
imaging with neuropathological and neurophysiological analyses defines the extent of neuronal
impairments in murine human immunodeficiency virus type-1 encephalitis. J Neurosci Res.
2005 Vol. 80(4): 562-75.

Potula R, Poluektova L, Knipe B, Chrastil J, Heilman D, Dou H, Takikawa O, Munn DH,
Gendelman HE, Persidsky Y. Inhibition of Indoleamine 2,3-dioxygenase (IDO) enhances
elimination of virus-infected macrophages in animal model of HIV-1 encephalitis. Blood. 2005
Vol. 106(7): 2382-90.

Kingsley JD, Dou H, Morehead J, Rabinow BE, Gendelman HE, Destache CJ.
2
PI: Dou, Huanyu
Nanotechnology: A Focus on Nanoparticles as a Drug Delivery System. Journal of
Neuroimmune Pharmacology. 2006 (1): 340-350.

Dou H, Ellison H, Bradley J, Kasiyanov A, Poluektova L, Xiong H, Maggirwar S, Dewhurst S,
Gelbard HA, and Gendelman HE. Neuroprotective mechanisms of lithium in murine HIV-1
encephalitis. J Neurosci, 2005 Vol. 25(37): 8375-85.

Potula R, Haorah J, Knipe B, Leibhart J, Chrastil J, Heilman D, Dou H, Reddy R, Ghorpade A,
Persidsky Y. Alcohol abuse enhances neuroinflammation and impairs immune responses in
an animal model of human immunodeficiency virus-1 encephalitis. Am J Pathol. 2006 Vol.
168(4): 1335-44.

Dou H, Morehead J, Bradley J, Gorantla S, Ellison B, Kingsley J, Smith LM, Chao W,
Bentsman G, Volsky DJ, Gendelman HE. Neuropathologic and neuroinflammatory activities of
HIV-1-infected human astrocytes in murine brain. Glia. 2006 Vol. 54(2): 81-93.

Dou H, Destache CJ, Morehead JR, Mosley RL, Boska MD, Kingsley J, Gorantla S,
Poluektova L, Nelson JA, Chaubal M, Werling J, Kipp J, Rabinow BE, Gendelman HE.
Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery.
Blood. 2006 Vol. 108(8): 2827-35.

Gorantla S, Dou H, Boska M, Destache CJ, Nelson J, Poluektova L, Rabinow BE, Gendelman
HE, Mosley RL. Quantitative magnetic resonance and SPECT imaging for macrophage tissue
migration and nanoformulated drug delivery. J Leukoc Biol. 2006 Vol. 80(5): 1165-74.

Peng H, Erdmann N, Whitney N, Dou H, Gorantla S, Gendelman HE, Ghorpade A, Zheng J.
HIV-1-infected and/or immune activated macrophages regulate astrocyte SDF-1 production
through IL-1beta. Glia. 2006 Vol. 54(6): 619-29.

Dou H, Morehead J, Destache CJ, Kingsley JD, Shlyakhtenko L, Zhou Y, Chaubal M, Werling
J, Kipp J, Rabinow BE, Gendelman HE. Laboratory investigations for the morphologic,
pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocytederived macrophages. Virology. 2007 Vol.358(1): 148-58.

Gorantla S, Liu J, Sneller H, Dou H, Holguin A, Smith L, Ikezu T, Volsky DJ, Poluektova L,
Gendelman HE. Copolymer-1 Induces Adaptive Immune Anti-inflammatory Glial and
Neuroprotective Responses in a Murine Model of HIV-1 Encephalitis. J Immunol. 2007 Vol.
179(7): 4345-56.

Peng H, Whitney N, Wu Y, Tian C, Dou H, Zhou Y, Zheng J. HIV-1-infected and/or immuneactivated macrophage-secreted TNF-alpha affects human fetal cortical neural progenitor cell
proliferation and differentiation.Glia. 2008 Jun;56(8):903-16.

Liu Y, Uberti MG, Dou H, Banerjee R, Grotepas CB, Stone DK, Rabinow BE, Gendelman HE,
Boska MD. Ingress of blood-borne macrophages across the blood-brain barrier in murine HIV1 encephalitis. J Neuroimmunol. 2008 Aug 30;200(1-2):41-52.

Potula R, Ramirez SH, Knipe B, Leibhart J, Schall K, Heilman D, Morsey B, Mercer A,
Papugani A, Dou H, Persidsky Y. Peroxisome proliferator-activated receptor-gamma activation
3
PI: Dou, Huanyu
suppresses HIV-1 replication in an animal model of encephalitis. AIDS. 2008 Aug
20;22(13):1539-49

Beduneau A, Ma Z, Grotepas CB, Kabanov A, Rabinow BE, Gong N, Mosley RL, Dou H,
Boska MD, Gendelman HE. Facilitated monocyte-macrophage uptake and tissue distribution of
superparmagnetic iron-oxide nanoparticles. PLoS One. 2009;4(2):e4343.

Dou H, Grotepas CB, Zeng C, Boska MD, Destache CJ, Chaubal M, Werling J, Kipp J, Rabinow
BE, Gendelman HE. Macrophage delivery of nanoformulated anti retroviral drug to the brain in
a murine model of neuroAIDS. J. of Immunology, 2009 Jul 1;183(1):661-9.

Nowacek AS, Miller RL, McMillan J, Kanmogne G, Kanmogne G, Mosley RL, Ma Z, Graham
S, Chaubal M, WerlingJ, Rabinow R, Dou H, and Gendelman HE. NanoART Synthesis,
Characterization, Uptake, Release, and Toxicology for Human Monocyte-Macrophage Drug
Delivery. J. of Immunology, in submission.
Invited Talks:
1. December 5, 2008. Research seminar Department of anatomy, Philadelphia College of
Osteopathic Medicine, Philadelphia, PA
2. January 9, research seminar, Department of Neurology & Pittsburgh Institute of
Neurodegenerative Disease, University of Pittsburg, Pittsburg, PA
3. April 27, 2009, research seminar, Department of Public Health Sciences, University of Hawaii
at Manoa
4. April 30, 2009, COBRE/APITMID Seminar Series, John A. Burns School of Medicine,
University of Hawaii at Manoa
5. Invited speaker, First World Congress of International Academy of Nanomedicine (IANM). Jun
12-13, 2009, Sanya, Hainan, China
6. Invited speaker, NIDA cutting Edge Seminar, Tuesday, September 1, 2009, Bethesda, MD
20892
4